Pharma Focus America

Genezen Has Acquired Uniqure's Gene Therapy Manufacturing Operations Located in Lexington, MA

Tuesday, July 02, 2024

Genezen, a prominent gene therapy contract development and manufacturing organization (CDMO), has announced its acquisition of uniQure's commercial gene therapy operations based in Lexington, MA. This acquisition includes securing a state-of-the-art viral vector manufacturing facility and a highly skilled team. Genezen will also establish strategic supply agreements for uniQure's clinical portfolio and CSL's HEMGENIX® product, the first one-time gene therapy approved in the U.S. and Europe for severe and moderately severe Hemophilia B.

Located near Boston, the Lexington site holds a commercial license for viral vector production, expanding Genezen's capabilities from preclinical stages through late-phase and commercial manufacturing. The facility includes advanced laboratory spaces and a pilot plant, designated as Genezen's global center of excellence for adeno-associated virus (AAV) production. This acquisition complements Genezen's existing operations in Indianapolis, IN, enhancing its scale and specialized capabilities.

Genezen, expressed enthusiasm for the acquisition, highlighting its alignment with Genezen's mission to advance cell and gene therapies through top-tier development and manufacturing solutions. He emphasized the immediate benefits for current and future customers, underscoring Genezen's commitment to supporting advancements in therapeutic development.

uniQure, emphasized the strategic fit of the transaction, ensuring continued access to high-quality manufacturing capabilities and retaining a dedicated team integral to the facility's success. The partnership aims for a seamless transition to maintain support for therapeutic innovation.

Mike Deem, Head of CSL Behring Operations, welcomed the expanded collaboration with Genezen, reinforcing their commitment to reliable supply chains for patient therapies.

Financially, the transaction includes growth equity from Ampersand Capital Partners, enabling Genezen to further expand its operations across multiple sites and execute its long-term growth strategy.

Overall, the acquisition positions Genezen as a pivotal player in gene therapy manufacturing, poised to deliver innovative solutions and support to the global biopharmaceutical industry.

 

Source: prnewswire.com

Thermo Fisher Scientific - mRNA ServicesFuture Labs Live USA 2024World Vaccine Congress Europe 2024World Orphan Drug Congress 2024Advanced Therapies USA 2024World Orphan Drug Congress Europe 2024